VK2735 (Viking Therapeutics): The Zepbound Challenger in Trials

Why VK2735 gets so much attention

VK2735 targets the exact receptor combination that made tirzepatide the strongest approved weight loss drug — GLP-1 + GIP — but Viking is developing it as both a weekly injection and a daily oral pill. No approved dual-agonist pill exists; a successful oral VK2735 would be a first. Viking is a small-cap biotech, which is why the stock community watches every data release closely.

What the trials show so far

• Injectable (Phase 2): up to ~14.7% weight loss at 13 weeks — a steep early trajectory; longer treatment in trials suggests a path toward ~20%.
• Oral (early Phase 1/2): ~8% at 28 days — meaningful for a pill, still early.
• Side effects: primarily GI (nausea, vomiting, diarrhea) — the same class effects as existing GLP-1/GIP drugs, mostly mild-to-moderate.

For context on how these numbers compare to what's approved, see Zepbound vs Mounjaro and the full GLP-1 pipeline guide.

The gray-market warning

Because VK2735 is unapproved, anything sold online as "VK2735" is unregulated research chemical — no verified purity, dosing, or sterility. The same warning applies to retatrutide, which is also frequently counterfeited. Legitimate access to VK2735 exists only through clinical trial enrollment.

Realistic timeline

Phase 3 obesity trials typically run 1.5-2 years of enrollment and treatment, plus FDA review time. Even with a smooth path, commercial availability is realistically 2027-2028 or later — and pipeline drugs fail or delay regularly. Meanwhile, oral options are closer: see Foundayo (orforglipron) and amycretin.

Frequently asked questions

What is VK2735?

VK2735 is Viking Therapeutics' experimental weight loss drug — a dual agonist activating both GLP-1 and GIP receptors, the same mechanism as tirzepatide (Zepbound/Mounjaro). Viking is developing it in both injectable and oral forms, which is unusual and potentially disruptive.

How much weight does VK2735 help you lose?

Phase 2 injectable data showed up to ~14.7% weight loss at 13 weeks — on a trajectory toward or past 20% with longer treatment. The oral version showed ~8% at 28 days in early data. Final numbers await larger, longer Phase 3 trials.

Is VK2735 approved by the FDA?

No. VK2735 is investigational only — it cannot be prescribed, purchased, or legally obtained outside clinical trials. Anyone selling 'VK2735' is selling an unregulated gray-market product.

When will VK2735 be available?

Viking has advanced the drug into Phase 3 development. Even on a fast timeline, approval is realistically 2027-2028 or later. Clinical trial enrollment through clinicaltrials.gov is the only legitimate current access.

What are the best alternatives available now?

Tirzepatide (Zepbound, ~21% loss) is the approved drug with the same dual mechanism — available through LillyDirect and telehealth. Compounded tirzepatide and semaglutide via licensed telehealth start at $119-$199/month for cash-pay access.

Bottom line

VK2735 could eventually become a legitimate Zepbound competitor — especially if the oral version works — but it's a trial-stage drug, and unapproved gray-market versions are actively dangerous. Tirzepatide delivers the same mechanism today, and compounded GLP-1s start at $119/month for patients who can't access or afford brands.